Salem Investment Counselors’s Adaptive Biotechnologies ADPT Stock Holding History

Salem Investment Counselors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.61K	Hold	215	–	–	﹤0.01%	1017
2026 Q1	$2.98K	Buy	+215	New	+$3.42K	﹤0.01%	1036
2023 Q3	–	Sell	-125	Closed	-$839	–	1104
2023 Q2	$839	Hold	125	–	–	﹤0.01%	1070
2023 Q1	$1.1K	Hold	125	–	–	﹤0.01%	1029
2022 Q4	$955	Hold	125	–	–	﹤0.01%	1005
2022 Q3	$1K	Hold	125	–	–	﹤0.01%	976
2022 Q2	$1K	Hold	125	–	–	﹤0.01%	1006
2022 Q1	$2K	Hold	125	–	–	﹤0.01%	915
2021 Q4	$4K	Hold	125	–	–	﹤0.01%	940
2021 Q3	$4K	Hold	125	–	–	﹤0.01%	858
2021 Q2	$5K	Hold	125	–	–	﹤0.01%	784
2021 Q1	$5K	Buy	+125	New	+$6.77K	﹤0.01%	749

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Salem Investment Counselors's ADPT Position: Q2 2026 in Review

Salem Investment Counselors held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 215 shares worth $4.61K. The position accounts for ﹤0.01% of the portfolio, ranked #1017.

Salem Investment Counselors first reported a position in ADPT in Q1 2021 and has held it in 12 quarters since. The position peaked at $5K in Q2 2021. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Salem Investment Counselors held 215 shares of Adaptive Biotechnologies worth $4.61K as of Q2 2026.
Salem Investment Counselors left its Adaptive Biotechnologies share count unchanged in Q2 2026.
Adaptive Biotechnologies made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #1017 holding.
Salem Investment Counselors first reported a position in Adaptive Biotechnologies in Q1 2021 and has held it in 12 quarters since.
Salem Investment Counselors's Adaptive Biotechnologies position peaked at $5K in Q2 2021.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.